HuDS6-DM4: Interim Phase I data

Interim data from 20 evaluable patients with refractory CAVI-positive solid tumors who received IV SAR566658 every 3 weeks at doses of >=120 mg/m 2 in an open-label, dose-escalation, international Pha...